Read our blog posts and announcements here!

We keep our blog alive by regularly publishing news, articles and updates about CT-N. We would like to create a place where important dialogues can arise. A place where you can share your ideas and concerns with us so that you find appropriate solutions. Our main goal is to provide added value that best meets your needs.

Sign up for our newsletter today, so you can stay informed about the ins and outs of our company.

Don't forget that we want to help you. So if you have any questions about who we are and what exactly we do, don't hesitate to contact us today.

Contact us

CT-N opens its Coordinating Center in the CZECH REPUBLIC

Button
Button
Button
Button

ClinTrial-Net (CT-N) takes great pleasure in announcing the expansion of our international services with the opening of its NEW coordinating center in Masečin, Štěchovice (near Prague) on the 1^st of September 2023.

By extending and bringing our outsourcing and centralized services to the Czech Republic, we aim to provide a more dynamic and greater strategic advantage to regional hospitals and life science businesses of all sizes in Middle (EU) Europe.

Please do not hesitate to share our common interest, excitement and questions by e-mailing us at contact-us@ct-n.eu.

TRI (Thrombosis Research Institute) and CT-N.
A successful collaborative story in recruitment strategy!

The ETHIC Study (Early Thromboprophylaxis In COVID-19) started worldwide on the 27th of October 2020 and was designed in response to recent evidence suggesting that severe COVID-19 infections are associated with increased frequency of thrombosis. These blood clots can lead to individuals being admitted to hospital, or, unfortunately in severe cases, death. Enoxaparin, a LMWH drug, is a blood-thinning drug which has been used by doctors and nurses in hospitals and general practices for many years to prevent the thickening of blood which may lead to a clot. It is easier for doctors to prevent new blood clots from forming than treating existing blood clots.

The ETHIC study aims to find out if giving enoxaparin in an early stage of COVID-19 disease can prevent individuals being admitted to hospitals and/or death.

The study is carried out in Belgium, Brazil, South Africa, Australia, UK, India and Spain, in approximately 30 to 50 centers.

The strategy for recruitment of patients in Belgium is being used as an example for the other countries. Dr Frank Cools, our ETHIC National Coordinating Investigator, gave below comment at the Recruitment Start in Belgium on 01 of November 2020:

Dr Frank Cools

ETHIC National Coordinating Investigator, Belgium

Chief of Cardiology at AZ Klina Hospital

"In Belgium, testing for Coronavirus is organized in so-called triage centers, manned by dedicated nurse and general practitioners. We aim to cooperate with these centers to identify potential study patients. A ‘flying study nurse’ (who will work with and visit the centers) will do the practical work-up.

Dedicated mobile nurses will visit the patients at home and give instructions to patients on how to administer study medication (for patients in the enoxaparin group) and how to fill out the patient diary. Whenever possible, we will provide remote care.

We are keenly aware of the challenges that lie ahead, but such challenges will always invite innovative solutions, and we believe the trial can contribute greatly to the research."

This strategy works splendidly: Belgium had the first patient included in Europe! There are, at the end of August 2021, 207 patients randomized worldwide.

So far, Belgium is the best pupil of the class worldwide with 83 patients recruited with the help of CT-N!

The whole team of CT-N is proud to be a part of this study.

At CT-N, we go the extra mile to achieve our goals!

Register now